CONTACT: sales@homenpatio.com
 

Lorbrexen 100mg Lorlatinib Tablets

  • $3,595.40$3,415.63

Lorbrexen 100mg Lorlatinib Tablets - YD1111009 - lung cancer drugs - Medicine DetailBrand Name: Lorbrexen Tablets  Active Ingredients: Lorlatinib 100mg  Manufactured by: Everest Pharmaceutical Strength: 100 mg  Form: Tablets Packing: Pack

Add to Wish List

Compare this Product

Ex Tax: $3,415.63

Availability: In Stock

Product Code: YD1111009

Medicine Detail


Brand Name: Lorbrexen Tablets 

Active Ingredients: Lorlatinib 100mg 

Manufactured by: Everest Pharmaceutical

Strength: 100 mg 

Form: Tablets

Packing: Pack of 30 Tablets 


Lorbrexen (Lorlatinib), generic Lorbrena is a prescription medicine. It is used to treat metastatic non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. These uses in patients who have already received alectinib, ceritinib or both crizotinib. At least 1 other medicine to treat NSCLC that is caused by the ALK gene.

Recommended Dosage

The recommended dosage of LORBRENA is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.

Swallow tablets whole and chew, crush or split tablets. Do not ingest broken tablets, cracked, or otherwise not intact.

Take Lorbrexen at the same time each day. One dose is missed, then take the missed dose. Unless the next dose is due within 4 hours. Please not take 2 doses at the same time to make up for a missed dose.

Do not take an additional dose if vomiting occurs after Lorbrexen but continue with the next scheduled dose.

Lorlatinib Dosage Modifications for Adverse Reactions

The recommended dose reductions are:

First dose reduction: Lorbrexen 100 mg orally once daily. Second dose reduction: LORBRENA 50 mg orally once daily 

Disease interactions Lorlatinib

There are 8 disease interactions with Lorbrexen which include:

  • interstitial lung disease
  • atrioventricular block
  • CNS effects
  • hepatotoxicity/hepatic impairment
  • hyperglycemia
  • hyperlipidemia
  • hypertension
  • severe renal impairment

For Healthcare Professionals

Applies to lorlatinib: oral tablet

Hematologic

Very common (10% or more): Anemia (52%), thrombocytopenia (23%), lymphopenia (22%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (23%), myalgia/musculoskeletal pain (17%), back pain (13%), pain in extremity (13%)[Ref]

Ocular

Very common (10% or more): Vision disorder (e.g., diplopia, photophobia, photopsia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters) (15%)[Ref]

Metabolic

Most common (10% or more): Hypercholesterolemia (96%), hypertriglyceridemia (90%), edema (edema peripheral, eyelid edema, face edema, generalized edema, localized edema, periorbital edema, peripheral swelling, swelling) (57%), hyperglycemia (52%), hypoalbuminemia (33%), weight gain (24%), increased lipase (24%), increased alkaline phosphatase (24%), increased amylase (22%), hypophosphatemia (21%), hyperkalemia (21%), hypomagnesemia (21%), Grade 3 or 4 elevations in total cholesterol 17%), Grade 3 or 4 elevations in triglycerides (17%)[Ref]

Psychiatric

Common (10% or more): Cognitive effects (e.g., amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment, attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, reading disorder) (29%), changes in mood (24%), changes in sleep (e.g., abnormal dreams, insomnia, nightmare, sleep disorder, sleep talking, somnambulism) (10%)

Common (1% to 10%): Hallucinations, mental status changes, (10%)[Ref]

Hepatic

Very common (10% or more): Grade 4 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer (50%), Grade 3 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer (33%)

Common (1% to 10%): Grade 2 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer[Ref]

Respiratory

Very common (10% or more): Dyspnea (27%), cough (18%), upper respiratory tract infection (e.g., fungal upper respiratory infection, viral upper respiratory infection) (12%)

Common (1% to 10%): Interstitial lung disease (ILD), pneumonitis[Ref]

Reviews

There are no reviews for this product.

Write a review

Note: HTML is not translated!